128 related articles for article (PubMed ID: 22374735)
21. Tissue distribution and elimination of [14C]apixaban in rats.
Wang L; He K; Maxwell B; Grossman SJ; Tremaine LM; Humphreys WG; Zhang D
Drug Metab Dispos; 2011 Feb; 39(2):256-64. PubMed ID: 21071521
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of the new pyrimidine derivative NS-7, a novel Na+/Ca2+ channel blocker. 2nd communication: tissue distributions, placental transfer and milk secretion of radioactivity after a single intravenous 14C-NS-7 injection to rats.
Nonaka K; Tsujioka T; Tougou K; Mukai H
Arzneimittelforschung; 2003; 53(10):695-700. PubMed ID: 14650361
[TBL] [Abstract][Full Text] [Related]
23. Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models.
Nakahara T; Kita A; Yamanaka K; Mori M; Amino N; Takeuchi M; Tominaga F; Kinoyama I; Matsuhisa A; Kudou M; Sasamata M
Cancer Sci; 2011 Mar; 102(3):614-21. PubMed ID: 21205082
[TBL] [Abstract][Full Text] [Related]
24. Absorption, distribution, metabolism and excretion of [14C]ebastine after a single administration in rats.
Fujii T; Matsumoto S; Amejima H; Hatoyama T; Nakao M; Kagemoto A; Tanaka K; Miyazaki H
Arzneimittelforschung; 1994 Apr; 44(4):527-38. PubMed ID: 7912071
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics of NS-49, a phenethylamine class alpha 1A-adrenoceptor agonist. 4th communication: tissue distribution, placental transfer and milk secretion of radioactivity in rats after a single oral administration of 14C-NS-49, and effects of repeated administration on its pharmacokinetics.
Dalrymple PD; Beeby TL; Mukai H; Chasseaud LF
Arzneimittelforschung; 2001; 51(5):394-401. PubMed ID: 11413740
[TBL] [Abstract][Full Text] [Related]
26. Placental transfer and pharmacokinetics of a single dermal dose of [14C]methyl parathion in rats.
Abu-Qare AW; Abdel-Rahman AA; Kishk AM; Abou-Donia MB
Toxicol Sci; 2000 Jan; 53(1):5-12. PubMed ID: 10653515
[TBL] [Abstract][Full Text] [Related]
27. Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines.
Iwasa T; Okamoto I; Suzuki M; Nakahara T; Yamanaka K; Hatashita E; Yamada Y; Fukuoka M; Ono K; Nakagawa K
Clin Cancer Res; 2008 Oct; 14(20):6496-504. PubMed ID: 18927289
[TBL] [Abstract][Full Text] [Related]
28. Fetal and maternal tissue distribution of the new fluoroquinolone DW-116 in pregnant rats.
Shin HC; Kim JC; Chung MK; Jung YH; Kim JS; Lee MK; Amidon GL
Comp Biochem Physiol C Toxicol Pharmacol; 2003 Sep; 136(1):95-102. PubMed ID: 14522602
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics of prulifloxacin. 2nd communication: pharmacokinetics and effect on hepatic drug-metabolizing enzyme activities after repeated administration and transfer into fetus and milk after a single administration in rats.
Okuyama Y; Momota K; Morino A
Arzneimittelforschung; 1997 Mar; 47(3):285-92. PubMed ID: 9105547
[TBL] [Abstract][Full Text] [Related]
30. Disposition and metabolism of [14C]-haloperidol in rats.
Miyazaki H; Matsunaga Y; Nambu K; Oh-e Y; Yoshida K; Hashimoto M
Arzneimittelforschung; 1986 Mar; 36(3):443-52. PubMed ID: 3707663
[TBL] [Abstract][Full Text] [Related]
31. [Placental transfer and mammary excretion of [14C] T-3761 in rats and mice].
Hayakawa H; Hayashi K; Nakafuku K; Takano Y; Takagi H; Nakajima Y
Jpn J Antibiot; 1995 May; 48(5):686-91. PubMed ID: 7637203
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics of sepantronium bromide (YM155), a small-molecule suppressor of survivin, in Japanese patients with advanced solid tumors: dose proportionality and influence of renal impairment.
Aoyama Y; Nishimura T; Sawamoto T; Satoh T; Katashima M; Nakagawa K
Cancer Chemother Pharmacol; 2012 Sep; 70(3):373-80. PubMed ID: 22806304
[TBL] [Abstract][Full Text] [Related]
33. Induction of autophagy-dependent apoptosis by the survivin suppressant YM155 in prostate cancer cells.
Wang Q; Chen Z; Diao X; Huang S
Cancer Lett; 2011 Mar; 302(1):29-36. PubMed ID: 21220185
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of [125I]-recombinant human interleukin-11: 2. Placental transfer and excretion into milk after subcutaneous administration to rats.
Uchida T; Aoyama K; Mori K; Usui T; Watanabe T; Takariki Y; Asahara N; Hirose M; Kimura T; Tateishi M; Higuchi S
Eur J Drug Metab Pharmacokinet; 1998; 23(3):411-6. PubMed ID: 9842985
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics, distribution, metabolism and excretion of.
Yasoshima K; Kuwabara T; Fuse E; Kuramitu T; Kurata N; Nishiie H; Oishi T; Kobayashi H; Kobayashi S
Cancer Chemother Pharmacol; 2001; 47(2):106-12. PubMed ID: 11269735
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of miglitol. Absorption, distribution, metabolism, and excretion following administration to rats, dogs, and man.
Ahr HJ; Boberg M; Brendel E; Krause HP; Steinke W
Arzneimittelforschung; 1997 Jun; 47(6):734-45. PubMed ID: 9239452
[TBL] [Abstract][Full Text] [Related]
37. Tissue distribution of YM758, a novel If channel inhibitor, in pregnant and lactating rats.
Umehara KI; Seya K; Iwatsubo T; Noguchi K; Usui T; Kamimura H
Xenobiotica; 2008 Oct; 38(10):1274-88. PubMed ID: 18800311
[TBL] [Abstract][Full Text] [Related]
38. Distribution of carbon-14 labeled C60 ([14C]C60) in the pregnant and in the lactating dam and the effect of C60 exposure on the biochemical profile of urine.
Sumner SC; Fennell TR; Snyder RW; Taylor GF; Lewin AH
J Appl Toxicol; 2010 May; 30(4):354-60. PubMed ID: 20063269
[TBL] [Abstract][Full Text] [Related]
39. [Studies on absorption, distribution and excretion of 14C labeled (+-)-7-(3-amino-1-pyrrolidinyl)-6-fluoro-1-(2,4-difluorophenyl)-1,4- dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid p-toluene-sulfonate hydrate (14C-T-3262) in rats and mice].
Maeda T; Sakai H; Hayakawa H; Hayashi K; Yoneda K
Jpn J Antibiot; 1989 Apr; 42(4):854-67. PubMed ID: 2769938
[TBL] [Abstract][Full Text] [Related]
40. Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs.
Iwasa T; Okamoto I; Takezawa K; Yamanaka K; Nakahara T; Kita A; Koutoku H; Sasamata M; Hatashita E; Yamada Y; Kuwata K; Fukuoka M; Nakagawa K
Br J Cancer; 2010 Jun; 103(1):36-42. PubMed ID: 20517311
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
